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A genome-wide association study 
suggests the HLA Class II region as 
the major susceptibility locus for 
IgA vasculitis
Raquel López-Mejías  1, F. David Carmona2,3, Santos Castañeda4, Fernanda Genre1, Sara 
Remuzgo-Martínez1, Belén Sevilla-Perez5, Norberto Ortego-Centeno5, Javier Llorca6, Begoña 
Ubilla1, Verónica Mijares1, Trinitario Pina1, José A. Miranda-Filloy7, Antonio Navas Parejo8, 
Diego de Argila9, Maximiliano Aragües9, Esteban Rubio10, Manuel León Luque10, Juan María 
Blanco-Madrigal11, Eva Galíndez-Aguirregoikoa11, David Jayne12, Ricardo Blanco1, Javier 
Martín2 & Miguel A. González-Gay1,13,14
The genetic component of Immunoglobulin-A (IgA) vasculitis is still far to be elucidated. To increase the 
current knowledge on the genetic component of this vasculitis we performed the first genome-wide 
association study (GWAS) on this condition. 308 IgA vasculitis patients and 1,018 healthy controls from 
Spain were genotyped by Illumina HumanCore BeadChips. Imputation of GWAS data was performed 
using the 1000 Genomes Project Phase III dataset as reference panel. After quality control filters and 
GWAS imputation, 285 patients and 1,006 controls remained in the datasets and were included in 
further analysis. Additionally, the human leukocyte antigen (HLA) region was comprehensively studied 
by imputing classical alleles and polymorphic amino acid positions. A linkage disequilibrium block of 
polymorphisms located in the HLA class II region surpassed the genome-wide level of significance 
(OR = 0.56, 95% CI = 0.46–0.68). Although no polymorphic amino acid positions were associated at the 
genome-wide level of significance, P-values of potential relevance were observed for the positions 13 
and 11 of HLA-DRB1 (P = 6.67E-05, P = 1.88E-05, respectively). Outside the HLA, potential associations 
were detected, but none of them were close to the statistical significance. In conclusion, our study 
suggests that IgA vasculitis is an archetypal HLA class II disease.
Immunoglobulin-A (IgA) vasculitis, also known as Henoch-Schöenlein purpura (HSP), is the most common type 
of primary small-sized blood vessel leukocytoclastic vasculitis in children, although it may also develop in adults1. 
Although the classic clinical triad of IgA vasculitis consists of palpable purpura (involving the lower extremities), 
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joints and the gastrointestinal tract, renal complications may also develop in affected individuals2. In this regard, 
the outcome of IgA vasculitis patients is related to the presence of glomerulonephritis, which may lead to chronic 
renal failure1, 2.
IgA vasculitis has a multifactorial etiology in which both environmental and genetic factors seem to contrib-
ute to the predisposition and clinical phenotype of the disease1, 3. However, the genetic component of this type of 
vasculitis remains poorly understood, as only a few candidate gene studies have been performed to date4, 5.
Unlike the candidate gene approach, genome-wide association studies (GWAS) imply a hypothesis free analy-
sis of hundreds of thousands of single-nucleotide polymorphisms (SNPs) across the whole genome6. This strategy 
has proven to be a powerful tool to unravel the genetic component of complex diseases during the last decade, 
including primary vasculitides such as Takayasu Arteritis, Behçet disease, and antineutrophil cytoplasmic anti-
body (ANCA)-associated vasculitis (AAV)7.
This study aimed at conducting the first GWAS of IgA vasculitis using the largest series of IgA vasculitis 
patients of European ancestry ever assessed for a genetic study.
Patients and Methods
Study population. A series of 308 patients diagnosed with IgA vasculitis and 1,018 unaffected and unre-
lated controls were genotyped in this study. The total number of individuals that passed the quality control (QC) 
filters mentioned below and were finally included in further analysis was 1,291 (285 and 1,006 for IgA vasculitis 
patients and controls, respectively). All subjects were from Spain and had European ancestry. IgA vasculitis con-
dition was diagnosed accordingly with both the guidelines included in Michel et al.8 and the American College 
of Rheumatology classification criteria for this form of vasculitis9. A description of the main clinical features of 
the IgA vasculitis patients and controls analyzed after QC filters is shown in Supplementary Table S1. For exper-
iments involving humans and the use of human blood samples, all the methods were carried out in accordance 
with the approved guidelines and regulations, according to the Declaration of Helsinki. All experimental proto-
cols were approved by the Ethics Committees of clinical research of the Spanish regions of Galicia, Cantabria, 
Madrid, Andalucía, and País Vasco. All participants or their parents signed an informed consent form before 
being enrolled in the study.
Genotyping and quality controls. Genomic DNA was extracted from peripheral blood samples using 
standard methods. Genotyping was conducted using the GWAS platform “Infinium® HumanCore Beadchip” in 
an iScan System (Illumina, Inc) and following the manufacturer’s protocol.
Raw data were subjected to the following QC filters using PLINK v.1.0710: (1) SNPs with cluster separation 
<0.4, call rates <0.98, minor allele frequencies (MAF) <0.01, and those deviating from Hardy-Weinberg equilib-
rium (HWE; P < 0.001) were excluded; (2) samples with call rates <0.95, and those with identity by descent >0.4 
were also removed. Sex chromosomes were not analyzed. The number of IgA vasculitis patients and controls that 
remained after each QC filter is shown in Supplementary Table S2.
Imputation of GWAS data. SNP genotype imputation throughout the genome was performed after initial 
QC using the 1000 Genomes Project (1KG) Phase III dataset as reference panel (www.1000genomes.org) and the 
software IMPUTE v.211. For that, we set the strand orientation, chromosome position, and SNP nomenclature 
accordingly with the build 37 (HG19) of the 1KG using PLNK. Imputation was carried out in individual chunks 
of 50,000 Mb covering whole-genome regions with a probability threshold for merging genotypes of 0.9 to max-
imize the quality of imputed variants. Imputed data were also subjected to the above mentioned QC filters in 
PLINK. Singletons were removed. Finally, possible population sub-stratification was controlled by principal com-
ponent (PC) analyses using PLINK and the gcta64 and R-base software under GNU Public license v2. To identify 
outliers, we calculated and plotted the ten first PCs of each individual, and those deviating >4 standard devia-
tions from the cluster centroid were excluded. PC analysis for the first three PCs for each individual are plotted 
Figure 1. Manhattan plot representation of the results of this study. The −log10 of the p values are plotted 
against their physical chromosomal position. The red line represents the genome-wide level of significance 
(P < 5E-08). A less stringent threshold (p < 1E-05) is highlighted in blue.
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in Supplementary Fig. The total number of SNPs that passed the QC and were finally analyzed was 1,909,910 
(2,581,927 and 2,185,351 for IgA vasculitis patients and controls, respectively). The number of polymorphisms 
that remained after each QC filter is shown in Supplementary Table S2.
Human leukocyte antigen (HLA) imputation. Considering that IgA vasculitis is an immune-mediated 
condition, a more comprehensive analysis of the HLA region was conducted. With that aim, we extracted the 
extended HLA region (29,000,000 to 34,000,000 bp in chromosome 6) from the non-imputed data and imputed 
SNPs, classical HLA alleles at two- and four-digits, and polymorphic amino acid positions as described12–16. In 
brief, to impute this genomic region, we used the SNP2HLA method with the Beagle software package and the 
Type 1 Diabetes Genetics Consortium (T1DGC) reference panel comprised of 5,225 individuals of European 
origin with genotyping data of 8,961 common SNPs and indel polymorphisms across the xMHC region, and 
SNP
Position in chr 
6 (GRCh37)
Reference 
allele P OR [CI 95%]
rs9275260 32.661.575 C 3.42E-09 0.56 [0.46–0.68]
rs9275259 32.661.572 C 3.42E-09 0.56 [0.46–0.68]
rs9275284 32.663.073 C 4.30E-09 0.56 [0.46–0.68]
rs9275285 32.663.080 A 4.30E-09 0.56 [0.46–0.68]
rs9275286 32.663.143 T 4.30E-09 0.56 [0.46–0.68]
rs9275288 32.663.203 A 4.30E-09 0.56 [0.46–0.68]
rs9275292 32.663.289 C 4.30E-09 0.56 [0.46–0.68]
rs9275244 32.660.881 G 4.92E-09 0.56 [0.46–0.68]
rs5000633 32.663.610 C 5.20E-09 0.56 [0.46–0.68]
rs2395522 32.664.722 A 5.25E-09 0.56 [0.46–0.68]
rs9275279 32.662.843 G 5.32E-09 0.56 [0.46–0.68]
rs9275281 32.662.920 G 5.32E-09 0.56 [0.46–0.68]
rs4248168 32.659.743 G 5.46E-09 0.56 [0.47–0.68]
rs9275224 32.659.878 A 5.46E-09 0.56 [0.47–0.68]
rs4713580 32.659.994 C 5.46E-09 0.56 [0.47–0.68]
rs4713584 32.660.237 C 5.46E-09 0.56 [0.47–0.68]
rs9275225 32.660.262 G 5.46E-09 0.56 [0.47–0.68]
rs5002704 32.659.279 T 5.67E-09 0.56 [0.46–0.68]
rs4713581 32.660.023 T 6.08E-09 0.56 [0.47–0.68]
rs4713583 32.660.153 T 6.08E-09 0.56 [0.47–0.68]
rs9275228 32.660.347 G 6.12E-09 0.56 [0.47–0.68]
rs9275227 32.660.337 C 6.12E-09 0.56 [0.47–0.68]
rs9275295 32.663.391 A 6.19E-09 0.56 [0.46–0.68]
rs9275277 32.662.677 G 7.33E-09 0.57 [0.47–0.69]
rs9275276 32.662.676 T 7.33E-09 0.57 [0.47–0.69]
rs9275245 32.660.943 A 7.89E-09 0.57 [0.47–0.69]
rs5002708 32.659.357 T 8.00E-09 0.57 [0.47–0.69]
rs5002707 32.659.337 T 8.00E-09 0.57 [0.47–0.69]
rs67838634 32.662.128 G 8.89E-09 1.76 [1.45–2.13]
rs9275222 32.659.516 T 1.28E-08 1.75 [1.44–2.12]
rs6457617 32.663.851 C 1.44E-08 0.57 [0.47–0.70]
rs6457620 32.663.999 G 1.44E-08 0.57 [0.47–0.70]
rs5002702 32.659.158 G 1.47E-08 0.57 [0.47–0.70]
rs9275226 32.660.311 C 1.49E-08 0.57 [0.47–0.70]
rs9275230 32.660.442 A 1.49E-08 0.57 [0.47–0.70]
rs5002705 32.659.319 C 1.60E-08 0.57 [0.47–0.70]
rs4713582 32.660.051 T 1.63E-08 0.57 [0.47–0.70]
rs4711304 32.660.170 T 1.65E-08 0.58 [0.47–0.70]
rs9275246 32.661.003 C 2.11E-08 0.58 [0.48–0.70]
rs4713587 32.659.535 G 2.36E-08 0.58 [0.48–0.70]
rs9275247 32.661.015 T 2.87E-08 0.58 [0.48–0.70]
rs9275231 32.660.505 C 2.81E-08 1.73 [1.42–2.09]
Table 1. Signals within HLA associated with IgA susceptibility at the GWAS significance level-P < 5E-08-after 
imputation of GWAS data. HLA: Human leukocyte antigen; IgA: Immunoglobulin-A; GWAS: genome-wide 
association study; SNP: single nucleotide polymorphism; chr: chromosome; OR: odds ratio; CI: confidence 
interval.
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four digits genotyping data of the HLA class I and II molecules12–16. Imputed HLA data were also filtered with 
PLINK with the following thresholds: success call rate >0.95 for alleles and amino acids, deviation from HWE 
(P < 0.001) for SNPs, and >0.95 total call rate for individuals. Information of a total of 7,179 SNPs, 423 classi-
cal HLA alleles (126 at two-digit and 297 at four-digit resolution) of the HLA-A, HLA-B, HLA-C, HLA-DRB1, 
HLA-DQB1, HLA-DQA1, HLA-DPB1 and HLA-DPA1 genes, and 1,275 amino acidic variants of the HLA system 
remained after the filters.
Statistical analyses. An estimation of the statistical power of the final cohort (285 IgA vasculi-
tis patients/1,006 healthy controls) was obtained with CaTS Power Calculator for Genetic Studies software 
(Supplementary Table S3).
To test for association, we compared the genotype frequencies of every SNP between cases and controls by 
logistic regression on the best-guess genotypes assuming an additive model in PLINK. The ten first PCs were 
included as covariates. In the case of the HLA region, we tested SNPs, classical HLA alleles and all possible com-
binations of amino acid residues per position. A likelihood ratio test of amino acid positions was also conducted, 
as described12.
P-values, odds ratios (OR), and 95% confidence intervals (CI) were then calculated. The statistical threshold 
was set at the genome-wide level of significance (P < 5E-08). In the HLA analysis, despite not interrogating the 
whole genome but a specific region of chromosome 6, we decided to maintain the statistical threshold at the 
genome-wide level of significance (P < 5E-08) to avoid possible false positive results.
Results
Figure 1 summarizes the overall results of the study. Several association signals in high linkage disequilibrium 
(LD, r2 > 0.8) at the genome-wide level of significance were disclosed within the HLA region at chromosome 6. 
The strongest signal corresponded to a disequilibrium block of polymorphisms (OR = 0.56, 95% CI = 0.46–0.68) 
(Table 1), which we refer to as rs9275260, that maps to an intergenic region in HLA class II between HLA-DQA1 
and HLA-DQB1. To confirm these results, we obtained direct genotypes of the Spanish cohort using a TaqMan 
probe for rs9275260. The overall concordance reached after comparing TaqMan types with the corresponding 
imputed data was 99.84%. Outside the HLA, some potential signals located in different intronic and intergenic 
regions were observed (Fig. 1), but none of them reached the statistical level of significance (Supplementary 
Table S4).
We tried to narrow down the HLA association with IgA vasculitis by inferring SNPs, classical HLA alleles, 
and polymorphic amino acid positions using as reference the T1DGC panel. Accordingly, association signals at 
the genome-wide level of significance were disclosed (Fig. 2A). The genetic variant rs9275224 represented the 
strongest peak (P = 5.74E-09, OR = 0.56, 95% CI = 0.46–0.68) (Supplementary Table S5). The polymorphism 
rs9275260 (and SNPs in high linkage disequilibrium with it) observed in the genome-wide data analysis was 
not detected in the analysis of the HLA region since 1KG Phase III dataset was not used as reference panel in 
Figure 2. Manhattan plot representation of the step-wise conditional logistic regression of the HLA region. 
(A) Unconditioned test of the HLA region. (B) Results of the HLA region after controlling for rs9275224. The 
−log10 of the p values are plotted against their physical chromosomal position. A red/green color gradient was 
used to represent the effect size of each analyzed variant (red for risk and green for protection). The red line 
represents the genome-wide level of significance (P < 5E-08).
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this analysis. Nevertheless, rs9275224 was in complete LD (r2 = 1) with rs9275260 (and, consequently, with all 
the SNPs of the same disequilibrium block) observed in the genome-wide data analysis, meaning that these pol-
ymorphisms represent the same signal. Although no polymorphic amino acid positions were associated at the 
genome-wide significance level, P-values of potential relevance were observed for the HLA-DRB1 positions 13 
and 11 (P = 6.67E-05 and P = 1.88E-05, respectively) (Supplementary Table S6). Conditional logistic regression 
analyses of the HLA data indicated that rs9275224 explained most of the HLA associated variants in HLA class II 
(Fig. 2B). Regarding HLA class I, a potential signal in HLA-B was observed (rs2523650, P = 1.10E-05, OR = 1.59, 
95% CI = 1.29–1.96).
Discussion
This study represents the first GWAS of IgA vasculitis. Consistent with the results obtained in a former study5, our 
data suggest the involvement of HLA class II region in the pathophysiology of IgA vasculitis, thus supporting the 
high relevance of the immune system in the development of this disease and suggesting that IgA vasculitis may 
be related to other class II vasculitides such as giant cell arteritis (GCA)12 or AAV17. The strongest signal mapped 
to the HLA-DQA1/DQB1 region, which is in high LD with the HLA-DRB1 gene. Consequently, the associated 
polymorphisms may be tagging a putative aetiologic variant at HLA-DRB1. Regarding polymorphic amino acid 
positions, none of the signals reached the genome-wide level of significance. Nevertheless, likewise rheumatoid 
arthritis13 and GCA12, the HLA-DRB1 positions 13 and 11 were amongst the strongest signals, which support 
the notion that IgA vasculitis may share immunopathogenic pathways with these conditions. On the other hand, 
after performing the conditional analysis on the HLA data, a potential signal that maps to HLA-B was observed, 
although it did not reach the genome-wide level of significance. This result could be indicating a potential effect of 
HLA class I in the pathogenesis of IgA vasculitis, as previously proposed4. In addition, no consistent associations 
with IgA vasculitis susceptibility were detected outside the HLA region, probably due to an insufficient statistical 
power to detect risk variants with a moderate effect.
Vasculitides constitute a heterogeneous group of diseases that often have overlapping clinical and pathological 
manifestations18. Nevertheless, differences between them in molecular terms have been described7. In this regard, 
the results derived from our study classify IgA vasculitis as a HLA class II condition linking it to GCA and AAV. 
Nonetheless, it is important to keep in mind that the number of cases recruited in our study was not high and 
replication was not carried out. Because of that, further confirmatory studies in independent populations should 
be performed to validate our data.
In summary, our results suggest that IgA vasculitis is an archetypal HLA class II disease.
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